Prevention and Treatment of Hyperphosphatemia
Vervloet, M. G., & Ballegooijen, A. J. (2018). Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney International, 93(5), 1060-1072.
The analysis method in this study is the generalization of the evidence base for the treatment and prevention of hyperphosphatemia. The study is based on a review of tests conducted on animals to prove the pathological effect of phosphate; further, various methods of treating hyperphosphatemia are considered. The authors of the study adhere to the adverse impact of a large number of food phosphates. The sample consists of patients with CKD who are undergoing therapy to prevent an increase in the concentration of phosphates. Data is collected by recording general blood test results and is analyzed during a mechanical comparison of the obtained indicators.
This study confirmed that hyperphosphatemia might be the final indicator of a phosphate imbalance. It identified FGF-23 as a promising therapeutic target that can improve the fatal prognosis in patients with CKD. According to Vervloet and Ballegooijen (2018), the combination of indicators of FGF-23, the level of P, and its fractional excretion will allow determining the beginning of control of MCS in CKD. Thus, it slows down the progression of CKD, the development of CVD, reduces adverse outcomes and increases patient survival.
The study proves the importance of developing more effective treatments for hyperphosphatemia and filling significant gaps in this area. It establishes that an increase in the level of FGF-23 in CKD is closely associated with the progression of renal failure, unfavorable cardiovascular outcomes, and mortality.
References
Chaiyakittisopon, K., Pattanaprateep, O., Ruenroengbun, N., Sapankaew, S., Ingsathit, A., Mckay, G. J., … Thakkinstian, A. (2021). Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: A systematic review and meta-analysis of the economic evaluations. The European Journal of Health Economics, 22(12), 571-584.
Cozzolino, M., Ciceri, P., & Galassi, A. (2019). Hyperphosphatemia: A novel risk factor for mortality in chronic kidney disease. Annals of Translational Medicine, 7(3), 55-63.
Fouque, D., Vervloet, M., & Ketteler, M. (2018). Targeting gastrointestinal transport proteins to control hyperphosphatemia in chronic kidney disease. Drugs, 78(15), 1171-1186.
Vervloet, M. G., & Ballegooijen, A. J. (2018). Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney International, 93(5), 1060-1072.
Wang, Q., Cui, Y., Yogendranath, P., & Wang, N. (2018). Blood pressure and heart rate variability are linked with hyperphosphatemia in chronic kidney disease patients. The Journal of Biological and Medical Rhythm Research, 35(10), 1329-1334.